Zimmer Biomet (NYSE:ZBH) expects revenue growth to improve in 2027 after exceeding its own expectations in each of the first three quarters of 2026, CEO Ivan Tornos said during a Jefferies fireside chat.
Tornos pointed to a diminishing headwind in China, progress in the company’s U.S. sales force t